Abstract
The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).
| Original language | English |
|---|---|
| Pages (from-to) | 313-323 |
| Number of pages | 11 |
| Journal | Cancer Investigation |
| Volume | 27 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2009 Mar 1 |
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Diagnostic and prognostic impact of osteopontin expression in endometrial cancer'. Together they form a unique fingerprint.
Cite this
Cho, H. B., Kang, E. S., Kim, Y. T., & Kim, J. H. (2009). Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Investigation, 27(3), 313-323. https://doi.org/10.1080/07357900802375738